Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 17, 2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 26, 2026
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.
Journal: JCO precision oncology
Published: March 06, 2025
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 16, 2024
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.
Journal: EClinicalMedicine
Published: July 10, 2024
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Journal: Cancer
Published: July 30, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Q and A.
Journal: JCO oncology practice
Published: February 23, 2023
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
Journal: Cancer research communications
Published: January 13, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 05, 2023
Anal Cancer: Emerging Standards in a Rare Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Journal: Investigational new drugs
Published: March 14, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: September 23, 2021
Last Updated: 09/26/2026